Tyrosine kinase inhibitors as induction therapy in nonsmall-cell lung cancer.

ABSTRACT:

Purpose of review

TKI therapy has shown excellent efficacy and favorable tolerability in patients with mutation-positive nonsmall cell lung cancer. However, there is no clear consensus on the role of TKI as induction therapy. In this article, we reviewed recently published studies to analyze the benefits of tyrosine kinase inhibitors, in particular, EGFR TKIs and ALK TKIs, as inducible treatments for NSCLC.

Recent findings

Several clinical trials have recently presented their latest data, giving analysis of patient's survival benefits and adverse events. Initial results have demonstrated promising efficacy and safety data. Some clinical case reports and retrospective analysis demonstrated that EGFR/ALK TKIs can significantly improve PFS and the rate of radical surgery. Howev

SUBMITTER: Gong J 

PROVIDER: S-EPMC7752212 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature